Second‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database.
Saved in:
| Title: | Second‐generation antipsychotic‐induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database. |
|---|---|
| Authors: | Ebina, Takumi (AUTHOR), Iwamoto, Kunihiro (AUTHOR), Ando, Masahiko (AUTHOR), Ikeda, Masashi (AUTHOR) |
| Source: | Psychiatry & Clinical Neurosciences. Mar2025, Vol. 79 Issue 3, p117-124. 8p. |
| Subjects: | Dystonia, Antipsychotic agents, Gender differences (Psychology), Delayed onset of disease, Data analysis, Drug side effects |
| Abstract: | Aim: This study aimed to explore the comparative risks for dystonia among different second‐generation antipsychotics (SGAs), the influence of sex, and the relationship between the time‐to‐onset of dystonia and its outcomes. Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted. We used the odds ratios to assess the reporting proportions among SGAs and sex, analyzed the median time‐to‐onset and interquartile ranges (IQRs), and conducted a receiver operating characteristic (ROC) curve analysis to investigate the time‐to‐onset of dystonia and its relationship to outcomes. Results: We extracted 9837 cases involving oral SGAs. Lurasidone was associated with a significantly higher proportion of dystonia reports than risperidone, aripiprazole, quetiapine, and olanzapine. The reporting proportion of dystonia associated with aripiprazole was lower than that of paliperidone and risperidone, but higher than that of quetiapine and olanzapine. Female sex was significantly associated with a higher reporting proportion of dystonia compared with males. Among the 148 cases of oral SGA‐induced dystonia, the median time‐to‐onset was 125 days (IQR, 19.75–453.25 days). Divided into the three outcome groups (recovered, improved, and unrecovered/residual), those with better outcomes had a shorter time‐to‐onset than those with poorer outcomes. ROC curve analysis suggested a threshold of 91.5 days for discriminating outcomes, with a sensitivity of 71.7% and specificity of 69.9%. Conclusions: The risks of dystonia may vary among SGAs and between sexes. SGA‐induced dystonia often manifests in the tardive form. [ABSTRACT FROM AUTHOR] |
| Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Aim: This study aimed to explore the comparative risks for dystonia among different second‐generation antipsychotics (SGAs), the influence of sex, and the relationship between the time‐to‐onset of dystonia and its outcomes. Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted. We used the odds ratios to assess the reporting proportions among SGAs and sex, analyzed the median time‐to‐onset and interquartile ranges (IQRs), and conducted a receiver operating characteristic (ROC) curve analysis to investigate the time‐to‐onset of dystonia and its relationship to outcomes. Results: We extracted 9837 cases involving oral SGAs. Lurasidone was associated with a significantly higher proportion of dystonia reports than risperidone, aripiprazole, quetiapine, and olanzapine. The reporting proportion of dystonia associated with aripiprazole was lower than that of paliperidone and risperidone, but higher than that of quetiapine and olanzapine. Female sex was significantly associated with a higher reporting proportion of dystonia compared with males. Among the 148 cases of oral SGA‐induced dystonia, the median time‐to‐onset was 125 days (IQR, 19.75–453.25 days). Divided into the three outcome groups (recovered, improved, and unrecovered/residual), those with better outcomes had a shorter time‐to‐onset than those with poorer outcomes. ROC curve analysis suggested a threshold of 91.5 days for discriminating outcomes, with a sensitivity of 71.7% and specificity of 69.9%. Conclusions: The risks of dystonia may vary among SGAs and between sexes. SGA‐induced dystonia often manifests in the tardive form. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13231316 |
| DOI: | 10.1111/pcn.13785 |
